Magazine Article | October 1, 2020

Why COGs Will Demand More Attention From Biosimilar Makers

Source: Life Science Leader

By Anna Rose Welch, Chief Editor, Biosimilar Development

The future sustainability of the biosimilar market will depend on several key factors, one of which is a reduction in the cost of goods (COGs). Without continued innovation in the manufacturing and analytical components of biosimilar development, the biosimilar value proposition becomes less feasible for pharma manufacturers.

For years, the need for a low-cost manufacturing approach to antibodies has been top of mind for Ard Tijsterman, CEO of virtual biotech BiosanaPharma. This has been especially true in the face of what he sees as a “genericized” biosimilar industry with steep pricing discounts.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: